AOD-9604 vs Tesamorelin

These two molecules are stacked together in the comparison hub because the search-intent question is the same — adipose-tissue-targeted protocols — even though the mechanisms are completely different. AOD-9604 is a synthetic fragment of human growth hormone (the C-terminal 16 amino acids) that was developed specifically to retain hGH's lipolytic effect without the broader IGF-1-mediated growth signal. Tesamorelin is a stabilized GHRH analog that drives endogenous GH release; the visceral-fat reduction effect is downstream of that broader GH signal rather than the direct lipolytic mechanism AOD-9604 was designed for.

Studied population matters here. Tesamorelin has a relatively mature evidence base because it is approved for HIV-associated lipodystrophy and was studied extensively for visceral adipose tissue reduction in that population. AOD-9604 has a thinner human evidence base; the lipolytic effect is well-supported in the preclinical work but the human trials in obesity were less definitive. A reader weighing the two molecules is also implicitly weighing the depth of the published clinical data behind each.

Cadence is very different between the two molecules. AOD-9604 protocols are typically once-daily subcutaneous at doses around 250–500 mcg; tesamorelin protocols are typically once-daily subcutaneous at doses around 1–2 mg. The per-dose milligram gap is roughly 4-to-1 in tesamorelin's favor, which means a vial of either molecule at the same concentration empties at very different rates. The vial-duration calculator linked below shows the difference at your own example vials.

Logging the two molecules is structurally similar — daily administration, waist circumference and body composition as the most-tracked endpoints, the usual fasting-glucose and morning-energy proxies that go with any GH-pathway protocol. The difference shows up in the fields that matter: an AOD-9604 log centers on the lipolytic endpoint alone because the molecule was designed to isolate that effect; a tesamorelin log usually also tracks the broader GH-signal proxies because the mechanism produces them whether you want them or not.

For the AOD-9604 vs Tesamorelin decision specifically, the calendar shape is what most readers underweight. AOD-9604's example vial is 5 mg drawn against 0.3 mg per dose at 7 doses per week. Tesamorelin's example vial is 5 mg drawn against 1 mg per dose at 7 doses per week. Those four numbers feed every column in the table above; change any one and the aod 9604 vs tesamorelin comparison shifts with it.

Concentration in this pair: AOD-9604 sits at 2.50 mg/mL on the example reconstitution; Tesamorelin sits at 2.50 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "AOD-9604 vs Tesamorelin" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 16 for AOD-9604 and 5 for Tesamorelin at the example dose sizes, with vial-duration windows near 2.3 weeks and 0.7 weeks respectively. Refill cadence follows directly from those windows, which is why the aod 9604 vs tesamorelin pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare AOD-9604 against Tesamorelin, the AOD-9604-side mistakes that show up most in logs are: Shaking the vial like a protein shake after adding water, which can damage the peptide. Injecting the reconstitution water directly onto the powder instead of down the side of the vial. Storing the mixed, liquid AOD-9604 vial at room temperature or in direct sunlight. Forgetting to refrigerate the vial after reconstitution, significantly shortening its lifespan. Each of these gets amplified when a reader is also actively comparing against Tesamorelin, because muscle memory from one molecule's unit math leaks into the other.

AOD-9604 question worth answering up front — What is AOD-9604 and how is it different from HGH? AOD-9604 is a small, modified piece of human growth hormone (HGH). It was created to isolate the fat-burning properties of HGH without affecting growth, muscle-building, or insulin levels, as it does not bind to the primary HGH receptor.

AOD-9604 question worth answering up front — What is AOD-9604 commonly tracked for? People use AOD-9604 to support fat metabolism and body composition goals. It is studied for its potential ability to stimulate the breakdown of existing fat (lipolysis) and inhibit the formation of new fat cells (lipogenesis).

On the Tesamorelin side of the AOD-9604 vs Tesamorelin decision, the recurring mistakes are: Assuming the per-dose volume and syringe draw will be as small as sermorelin's and failing to plan for a larger subcutaneous injection. Neglecting to systematically document and rotate injection sites, which can lead to localized lipohypertrophy that interrupts a planned daily schedule. Mistaking the typical milligram (mg) dose for micrograms (mcg) in the calculator, leading to a thousand-fold dosing error. Attempting to reconstitute a 5 mg vial with an excessively small diluent volume, making the large 1 mg dose difficult to measure and draw accurately. These are not generic dosing slips — they are the ones that compound when Tesamorelin is being logged in parallel with AOD-9604.

Tesamorelin question worth answering up front — Why is the Tesamorelin dose in milligrams (mg) when other GHRH analogs are often dosed in micrograms (mcg)? Tesamorelin's milligram-level dosing is a function of its molecular structure and the extensive clinical research that established its use profile. As the full 44-amino-acid GHRH sequence, its molecular weight and receptor affinity necessitate a larger mass to achieve the desired level of pituitary stimulation. The protocols for its FDA-approved indication were developed around a 1 mg or 2 mg daily dose, reflecting its distinct pharmacology compared to smaller, truncated peptide fragments.

Tesamorelin question worth answering up front — What specifically is the purpose of the trans-3-hexenoyl group on Tesamorelin? The trans-3-hexenoyl group is a fatty acid-based modification chemically bonded to the start of the peptide chain. Its sole purpose is to serve as a physical shield, sterically hindering the enzyme DPP-IV from accessing its cleavage site on the GHRH sequence. This protection from enzymatic degradation is what grants Tesamorelin a significantly longer half-life compared to native GHRH, which is its primary design advantage.